ABOS · Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Market Cap
15.62M
52 Wk Range
$0.19 - $3.60
Previous Close
$0.22
Open
$0.22
Volume
2,668,043
Day Range
$0.20 - $0.23
Enterprise Value
-36.81M
Cash
78.6M
Avg Qtr Burn
-26.65M
Insider Ownership
6.79%
Institutional Own.
67.64%
Qtr Updated
Sep 30th 2026
